Señales en vivo de CHGCY | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 15:59):

Stats
Volumen de hoy	76 389.00
Volumen promedio	183 993
Capitalización de mercado	54.17B
EPS	$0 ( 2024-04-25 )
Próxima fecha de ganancias	( $0 ) 2024-07-25
Last Dividend	$0.189 ( 2021-12-29 )
Next Dividend	$0 ( N/A )
P/E	26.13
ATR14	$0.0120 (0.07%)

Volumen Correlación

Largo: 0.07 (neutral)

Corto: 0.33 (neutral)

Signal:(55.489) Neutral

Chugai Pharmaceutical Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Chugai Pharmaceutical Correlación - Moneda/Commodity

0.41
( neutral )

0.00
( neutral )

-0.66
( moderate negative )

-0.30
( neutral )

Chugai Pharmaceutical Finanzas

Annual	2023
Ingresos:	$1 111.37B
Beneficio Bruto:	$693.01B (62.36 %)
EPS:	$197.83

FY	2023
Ingresos:	$1 111.37B
Beneficio Bruto:	$693.01B (62.36 %)
EPS:	$197.83

FY	2022
Ingresos:	$1 259.95B
Beneficio Bruto:	$783.70B (62.20 %)
EPS:	$227.64

FY	2021
Ingresos:	$999.76B
Beneficio Bruto:	$661.61B (66.18 %)
EPS:	$92.15

Financial Reports:

No articles found.

Chugai Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Chugai Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.15 - good (81.48%) | Divividend Growth Potential Score: 5.60 - Stable (12.07%)

Information

First Dividend	$0.138	2020-12-29
Last Dividend	$0.189	2021-12-29
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$0.463	--
Avg. Dividend % Per Year	0.00%	--
Score	3.09	--
Div. Sustainability Score	8.15
Div.Growth Potential Score	5.60
Div. Directional Score	6.88	--

Next Divdend (Est)
(2024-09-27)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

3.09

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
RWCB	Ex Dividend Knight	2023-07-28	Quarterly	0.00%
FFDF	Ex Dividend Knight	2023-08-01	Quarterly	0.00%
WTKWY	Ex Dividend Knight	2023-08-29	Annually	0.00%
MAAL	Ex Dividend Knight	2023-09-22	Quarterly	0.00%
CKHUY	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
SOBS	Ex Dividend Knight	2023-06-29	Quarterly	0.00%
HALMY	Ex Dividend Knight	2023-07-14	Semi-Annually	0.00%
AILLM	Ex Dividend Knight	2023-07-14	Quarterly	0.00%
NHYDY	Ex Dividend Knight	2023-05-11	Annually	0.00%
CRARY	Ex Dividend Junior	2023-05-25	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.315	1.500	3.70	5.55	[0 - 0.5]
returnOnAssetsTTM	0.172	1.200	4.27	5.12	[0 - 0.3]
returnOnEquityTTM	0.207	1.500	8.81	10.00	[0.1 - 1]
payoutRatioTTM	0.402	-1.000	5.98	-5.98	[0 - 1]
currentRatioTTM	5.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.21	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.937	1.500	0.351	0.526	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	16 118	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.677	1.000	2.05	2.05	[0.2 - 0.8]
operatingProfitMarginTTM	0.420	1.000	3.60	3.60	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.546	0.800	9.69	7.75	[0.5 - 2]
Total Score				8.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	12.70	1.000	8.82	0	[1 - 100]
returnOnEquityTTM	0.207	2.50	9.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.00876	1.500	9.78	0	[0 - 0.4]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.402	1.500	5.98	-5.98	[0 - 1]
pegRatioTTM	0.00187	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.371	1.000	3.23	0	[0.1 - 0.5]
Total Score				5.60

Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.